 Welcome folks, this is Jacob Schup with the 4PM stock market update. Take a look here, we're closing down about 0.84%, the ES mini about 2.69% in the Russell, NQ down about 1.09%, the Dow futures down 0.78%, gold down about 1.18%. Look at silver, really retracing here, down about 3% from its high of 0.26%. We have copper trading about sideways here, 3.87, excuse me, $3.87. Crude crashing down, oh maybe I'll talk about that tomorrow. Anyways, crude down quite a bit, we take a look, Tesla finishing the day down 4%, still dynamics just under the 120 mark, maybe seeing a new trade range coming here, which would be sweet. Again, that's a stock that has been at least for the last year actually pretty easy to predict the movements. DXY trading about 102.47%, Google sideways, Meta sideways, Disney up 1%. We'll take a look, I was looking at Eli Lilly on the break and just some other ones as well, some other biotech, Eli Lilly up about 4.31% today. This along with a lot of other ones too like Bloggins and all these kind of CRISPR therapeutics so on, there was a lot of FDA approvals last year. It was actually up nearly 50% for novel drugs last year than it was in 2022. That's putting it back on pace with historical levels. The FDA nods for innovative therapies containing an active ingredient or molecule not previously approved, rose to 55 in 2023, which is up from 37 in 2022 and 51 in 2021. You have this interesting thing going on, right? So this actually could be a positive in some case for the biotech. Now, the overarching issue is that investments into biotechs just going to be down because rates are so high. That obviously screws up some of the valuation that you have to do for things like biotech firms. However, more approvals does essentially bring in kind of lessons that fall, I would say, right? So we'll take a look a little bit more about that. If I'm filling in tomorrow, we will see folks. Thank you so much for joining me. Have a great rest of your evening and we'll see you tomorrow at 9am. We have Tommy O'Brien and we've got Basil, Steve, Larry, and then we'll see you about the three.